Microbiology Spectrum,
Год журнала:
2024,
Номер
13(1)
Опубликована: Ноя. 20, 2024
ABSTRACT
Neutralizing
antibody
titers
and
binding
levels
are
considered
correlates
of
protection
against
severe
SARS-CoV-2
infection.
The
clinical
utility
serology
should
be
reevaluated
in
light
the
emergence
escape
variants,
as
commercial
antibody-binding
assays
have
not
been
adapted
to
virus’
antigenic
evolution.
We
compared
anti-SARS-CoV-2
four
quantitative
serological
tests
based
on
variable
ancestral
spike
antigens
(three
in-house
ELISAs
prototype
VIDAS
IgG
QUANT
assay)
neutralization
pseudotyped
Wuhan,
BA.2,
BA.4/5,
BQ.1.1,
XBB.1.1
viruses
a
cohort
100
patients
infected
2020
or
during
Omicron
waves.
Binding
correlated
well
with
neutralizing
for
but
association
decreased
BQ.1.1
XBB.1
(for
assay,
Spearman’s
correlation
was
0.82
[95%
CI
0.74–0.88]
0.61
[0.46–0.72]
BA.2
XBB.1,
respectively).
In
15%
no
antibodies
assay
still
yielded
ranging
from
74
7,652
units/mL.
Using
an
adjusted
threshold
receiver
operating
characteristic
(ROC)
curve
analysis,
specificity
detection
increased
0.15
(95%
0.02–0.45)
0.17
(0.04–0.41)
0.92
(0.64–1.00)
0.83
(0.59–0.96)
respectively.
Serological
receptor-binding
domain
virus
fail
predict
activity
latest
circulating
variants.
Adapting
may
improve
their
immunocompromised
patients.
IMPORTANCE
Anti-SARS-CoV-2
developed
response
COVID-19
pandemic
diagnose
infection
monitor
individual’s
immunity
following
natural
vaccination.
Given
relationship
between
infection,
many
studies
evaluated
pre-Omicron
era.
An
important
potential
use
serology,
which
explores
antibodies,
is
estimating
level
new
particularly
immunosuppressed
individuals
those
at
risk
COVID.
However,
era,
evade
induced
by
previous
infections
vaccination,
determined
re-examined
order
determine
whether
these
optimized
adapting
strains.
International Journal of Infectious Diseases,
Год журнала:
2020,
Номер
101, С. 191 - 193
Опубликована: Сен. 28, 2020
ObjectivesWe
investigated
seroreactivity
by
using
a
commercial
SARS-CoV-2
ELISA
test
in
samples
collected
from
different
groups
of
individuals,
including
patients
diagnosed
to
have
Dengue,
Zika,
and
Chikungunya
infection
between
2015
2019,
an
endemic
area
the
Caribbean
Colombian
region.MethodsA
total
127
sera
obtained
six
individuals
were
included
this
study:
Group
A:
with
confirmed
infection;
B:
symptoms
suggestive
COVID-19
or
asymptomatic
contacts
patients;
C:
acute
recent
dengue
virus
D:
Zika
E:
previous
F:
exposure
spotted
fever
group
rickettsiae.ResultsOverall,
A,
B,
D
showed
92%,
75%,
26%
samples,
respectively;
furthermore,
C,
E,
F
100%
seronegativity.ConclusionsWe
found
serological
cross-reactivity
test.
Further
studies
are
needed
evaluate
whether
cross-reaction
is
maintained
time
nonacute
its
effect
serosurveys
areas
for
arbovirus.
Infection Control and Hospital Epidemiology,
Год журнала:
2020,
Номер
42(5), С. 604 - 608
Опубликована: Окт. 8, 2020
Abstract
In
this
prospective
cohort
of
1,012
Swiss
hospital
employees,
3
different
assays
were
used
to
screen
serum
for
SARS-CoV-2
antibodies.
Seropositivity
was
1%;
the
positive
predictive
values
lateral-flow
immunoassay
64%
(IgG)
and
13%
(IgM).
History
fever
myalgia
most
effectively
differentiated
seropositive
seronegative
participants.
Journal of Proteome Research,
Год журнала:
2025,
Номер
24(2), С. 499 - 514
Опубликована: Янв. 13, 2025
Since
late
2021,
Omicron
variants
have
dominated
the
epidemiological
scenario
as
most
successful
severe
acute
respiratory
syndrome
coronavirus
2
(SARS-CoV-2)
sublineages,
driving
new
and
breakthrough
infections
globally
over
past
two
years.
In
this
study,
we
investigated
for
first
time
host
salivary
response
of
COVID-19
patients
infected
with
(BA.1,
BA.2,
BA.4/5)
by
using
an
untargeted
four-dimensional
data-independent
acquisition
(4D-DIA)-based
proteomics
approach.
We
identified
137
proteins
whose
abundance
levels
differed
between
positive
negative
groups.
Salivary
signatures
were
mainly
enriched
in
ribosomal
proteins,
linked
to
mRNAviral
translation,
protein
synthesis
processing,
immune
innate,
antiapoptotic
signaling.
The
higher
14-3-3
(YWHAG,
YWHAQ,
YWHAE,
SFN)
saliva,
reported
here,
may
be
associated
increased
infectivity
improved
viral
replicative
fitness.
also
seven
(ACTN1,
H2AC2,
GSN,
NDKA,
CD109,
GGH,
PCYOX)
that
yielded
comprehension
into
infection
performed
outstandingly
screening
a
hospital
setting.
This
panel
presented
enhanced
anti-COVID-19
anti-inflammatory
signature,
providing
insights
disease
severity,
supported
comparisons
other
proteome
data
sets.
signature
provided
valuable
host's
SARS-CoV-2
infection,
shedding
light
on
pathophysiology
COVID-19,
particularly
cases
mild
disease.
It
underscores
potential
clinical
applications
saliva
settings.
Data
are
available
via
ProteomeXchange
identifier
PXD054133.
Scientific Reports,
Год журнала:
2025,
Номер
15(1)
Опубликована: Фев. 24, 2025
Neutralizing
antibody
titers
have
been
found
to
be
strongly
correlated
with
observed
vaccine
effectiveness
against
symptomatic
and
severe
COVID-19.
Few
non-high
complexity
assays
are
currently
available
detect
the
presence
of
neutralizing
antibodies.
This
retrospective
single-center
cross-sectional
study
compared
performance
a
lateral
flow
immunochromatography
assay
coupled
spectrophotometric
measurement
system
for
detecting
SARS-CoV-2
antibodies
an
enzyme-linked
immunosorbent
(ELISA)
neutralization
in
context
post-vaccination
responses.
The
limit
detection
was
similar
ELISA
strong
linearity
throughout
measuring
interval.
Repeatability,
interfering
substances,
cross-reactivity
studies
were
robust.
Results
274
plasma
samples
on
whom
RNA
test
vaccination
status,
including
number
manufacturer,
known
showed
positive
predictive
value
(PPV)
99.0%
(CI
96.4–99.7%)
negative
(NPV)
91.9%
83.4–96.2%)
ELISA.
PPV
all
manufacturer
subgroups
>
95%
except
those
individuals
who
had
only
1
Pfizer
(PPV
80%).
NPV
PCR
no
vaccinations
100%
while
88.1%
without
previous
or
vaccination.
80%
contrast
Moderna
vaccinations.
Alternative
methodologies
requiring
less
sophisticated
laboratory
support
measure
may
useful
Medical Science Monitor,
Год журнала:
2021,
Номер
27
Опубликована: Окт. 11, 2021
Recent
studies
on
the
pathogenesis
and
clinical
spectrum
of
human
disease
following
infection
with
new
pathogen,
SARS-CoV-2,
have
identified
varied
presentations
sequelae
COVID-19.
Acute
'cytokine
storm'
in
severe
COVID-19
results
multiorgan
damage
due
to
vascular
hyperpermeability,
edema,
hypercoagulation.
The
long-term
consequences
from
SARS-CoV-2
include
long
COVID.
or
post-COVID
syndrome,
multisystem
inflammatory
syndrome
children
(MIS-C).
Several
case
reports
adults
(MIS-A)
shown
presentation
at
more
than
four
weeks
after
initial
21
years
age.
In
September
2021,
a
published
systematic
review
literature
221
patients
MIS-A,
representing
most
comprehensive
study
date.
MIS-A
occurs
post-acute
period.
may
involve
dysregulated
antibody-mediated
immune
response,
similar
MIS-C.
Therefore,
respond
supportive
therapies
that
control
hyperinflammation.
This
Editorial
aims
describe
discuss
as
hyperinflammatory
terms
severity,
extent,
duration,
patient